NCT06282081View on ClinicalTrials.gov

Serum Neurofilament Light in Multiple Sclerosis

Active, not recruitingOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions
Multiple SclerosisRelapsing Remitting Multiple Sclerosis
Interventions
DIAGNOSTIC_TEST

Serum Neurofilament Light

The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.

Trial Locations (1)

14226

Dent Neurologic Institute, Amherst

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc., a subsidiary of F. Hoffman-La Roche AG

UNKNOWN

collaborator

Monogram Biosciences (LabCorp Specialty Testing Group)

UNKNOWN

lead

Dent Neuroscience Research Center

OTHER